Fundraising Fox

Tivorsan Pharmaceuticals

Los Angeles, US · Delaware corporation

Biotech

Founders & leadership

JN
John NicholsonNamed on SEC filing
JB
Joel BraunsteinNamed on SEC filing
JV
Jay VenkatesanNamed on SEC filing
MM
Michael MeyersNamed on SEC filing
JF
Justin FallonNamed on SEC filing
JC
James ConnollyNamed on SEC filing

Reported raises · per SEC filings

Form D private placements

$13.8M disclosed across 6 rounds · 2011–2018

▶$1.6MraisedOct 2018 · 8 investors · Pharmaceuticals
Rule 506(b)
Officers, directors & promoters on the filing
  • Jay VenkatesanDirector
  • Joel BraunsteinDirector
  • Michael MeyersExecutive Officer
  • Justin FallonDirector
  • James ConnollyDirector
  • John NicholsonDirector
Offering amount
$1.6M
Amount sold
$1.6M
Minimum investment
$80K
First sale
Nov 2014
Incorporated
Corporation, Delaware
Federal exemptions
06b
Full filing on SEC EDGAR ↗
▶$1.1MraisedOct 2018 · 2 investors · Pharmaceuticals
Rule 506(b)
Officers, directors & promoters on the filing
  • Michael MeyersExecutive Officer
  • James ConnollyDirector
  • Justin FallonDirector
  • Jay VenkatesanDirector
  • Joel BraunsteinDirector
  • John NicholsonDirector
Offering amount
$1.1M
Amount sold
$1.1M
Minimum investment
$250K
First sale
Feb 2011
Incorporated
Corporation, Delaware
Federal exemptions
06b
Full filing on SEC EDGAR ↗
▶$4.5MraisedOct 2018 · 32 investors · Pharmaceuticals
Rule 506(b)
Officers, directors & promoters on the filing
  • John NicholsonDirector
  • Justin FallonDirector
  • James ConnollyDirector
  • Michael MeyersExecutive Officer
  • Jay VenkatesanDirector
  • Joel BraunsteinDirector
Offering amount
$4.5M
Amount sold
$4.5M
Minimum investment
$10K
Sales commissions
$313.2K
Placement agents
T.R. Winston & Company, LLC
First sale
Mar 2017
Incorporated
Corporation, Delaware
Federal exemptions
06b
Full filing on SEC EDGAR ↗
▶$2.8MraisedOct 2018 · 14 investors · Pharmaceuticals
Rule 506(b)
Officers, directors & promoters on the filing
  • James ConnollyDirector
  • Jay VenkatesanDirector
  • Joel BraunsteinDirector
  • John NicholsonDirector
  • Justin FallonDirector
  • Michael MeyersExecutive Officer
Offering amount
$2.8M
Amount sold
$2.8M
Minimum investment
$25K
First sale
Feb 2013
Incorporated
Corporation, Delaware
Federal exemptions
06b
Full filing on SEC EDGAR ↗
▶$900KraisedOct 2018 · 4 investors · Pharmaceuticals
Rule 506(b)
Officers, directors & promoters on the filing
  • John NicholsonDirector
  • Joel BraunsteinDirector
  • Jay VenkatesanDirector
  • Michael MeyersExecutive Officer
  • Justin FallonDirector
  • James ConnollyDirector
Offering amount
$1M
Amount sold
$900K
Minimum investment
$25K
First sale
Jul 2018
Incorporated
Corporation, Delaware
Federal exemptions
06b
Full filing on SEC EDGAR ↗
▶$2.9MraisedOct 2018 · 35 investors · Pharmaceuticals
Rule 506(b)
Officers, directors & promoters on the filing
  • Justin FallonDirector
  • Michael MeyersExecutive Officer
  • James ConnollyDirector
  • Jay VenkatesanDirector
  • Joel BraunsteinDirector
  • John NicholsonDirector
Offering amount
$2.9M
Amount sold
$2.9M
Minimum investment
$5K
Sales commissions
$14.5K
Placement agents
T.R. Winston & Company, LLC
First sale
Jan 2016
Incorporated
Corporation, Delaware
Federal exemptions
06b
Full filing on SEC EDGAR ↗

Source: SEC EDGAR Form D. Amounts as filed; amended filings shown once at their latest values.

Frequently asked questions

How much funding has Tivorsan Pharmaceuticals raised?
Tivorsan Pharmaceuticals has disclosed $13.8M raised across 6 rounds.
Where is Tivorsan Pharmaceuticals headquartered?
Tivorsan Pharmaceuticals is headquartered in Los Angeles, US.